Lv13
50 积分 2021-01-08 加入
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
1天前
已关闭
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
1天前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
1天前
已完结
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
1天前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
1天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
9天前
已完结
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer
27天前
已完结
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity
1个月前
已完结
POS1079 Pharmacodynamic Response of JNJ-77242113 in Serum and Skin of Patients with Moderate-to-Severe Psoriasis: 1-Year Results from FRONTIER 1 & 2
1个月前
已关闭
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer
3个月前
已完结
皖公网安备34019202002308
